Delphi
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H) has released a DRAFT Innovative Solutions Opening (ISO) for the "Delphi" Program. This presolicitation aims to revolutionize biosensor technology by developing modular, chiplet-based wearable or ingestible sensors for continuous monitoring of deep biological information. This is a DRAFT ISO and not an invitation for solution summaries or proposals; any such responses will be disregarded.
Program Vision & Scope
The Delphi Program envisions empowering all Americans with a comprehensive understanding of their own bodies through continuous monitoring of biological markers like hormones, cytokines, and drug levels. Leveraging chiplet technology, the program seeks to significantly decrease cost, reduce size, weight, and power (SWaP), and enable broad access to cutting-edge biosensing capabilities. The ultimate goal is to quickly and cheaply develop modular wearable or ingestible sensors for early disease detection, continuous home recovery monitoring, and precision, closed-loop therapy management. The program will improve the biosensor development ecosystem by shifting to a chiplet-based architecture, allowing for reuse and remixing of components into high-performance devices.
Technical Requirements
Proposers for the future formal ISO will need to address four Technical Areas (TAs):
- TA1: Dry Chiplets Unique to Biosensing: Develop scalable packaging, interconnect strategies, ultra-low power management, and secure medical data transmission chiplets.
- TA2: Wet Biosensing Chiplets: Create biology-facing sensors integrated into chiplets for continuous tracking of low-concentration biochemical markers, requiring durable surface chemistries.
- TA3: Biocompatible Encapsulation: Design encapsulation strategies to protect electronics while selectively exposing sensors, ensuring biocompatibility and long-term reliability.
- TA4: Human Factors Testing or Clinical Trial: Develop a plan for either non-invasive human factors evaluation (for wellness) or minimally invasive human clinical trials (for FDA-regulated devices).
Contract Details & Timeline
This is a Presolicitation for a DRAFT ISO. The program is anticipated to be a 54-month, 3-phase effort, likely resulting in Multiple Other Transaction (OT) Agreements. Phase I is 24 months for component/process development, Phase II is 18 months for integration/preclinical testing, and Phase III is 12 months for clinical trials/human factors testing and scaling. Anticipated dates mentioned in the DRAFT ISO include a Proposer's Day on March 27, 2026, and future due dates for Solution Summaries (April 8, 2026) and Proposals (May 13, 2026). However, this DRAFT ISO is not currently accepting submissions.
Eligibility & Submission
This DRAFT ISO is open to a broad range of entities, including universities, non-profit organizations, small businesses, and other commercial entities. Federally Funded Research and Development Centers (FFRDCs) and government entities are generally prohibited unless they possess unique capabilities. Entities providing current professional support to ARPA-H are ineligible. Foreign entities may participate under specific regulations. Important Note: As this is a DRAFT ISO, ARPA-H is not currently accepting solution summaries or proposals, and any such responses will be disregarded. This notice is for informational and planning purposes only.
Contact Information
For inquiries, contact DELPHI ISO at DELPHI@arpa-h.gov.